Isthmus Partners LLC Purchases Shares of 7,331 Iradimed Corporation (NASDAQ:IRMD)

Isthmus Partners LLC purchased a new stake in Iradimed Corporation (NASDAQ:IRMDFree Report) during the fourth quarter, according to its most recent filing with the SEC. The fund purchased 7,331 shares of the medical equipment provider’s stock, valued at approximately $348,000. Isthmus Partners LLC owned about 0.06% of Iradimed as of its most recent filing with the SEC.

A number of other institutional investors and hedge funds also recently bought and sold shares of IRMD. Gladius Capital Management LP bought a new stake in Iradimed in the 3rd quarter valued at $36,000. AJOVista LLC purchased a new position in shares of Iradimed in the 4th quarter worth $66,000. Hsbc Holdings PLC purchased a new position in shares of Iradimed in the 3rd quarter worth $251,000. Summit Global Investments grew its stake in shares of Iradimed by 22.5% in the 4th quarter. Summit Global Investments now owns 7,088 shares of the medical equipment provider’s stock worth $336,000 after buying an additional 1,300 shares in the last quarter. Finally, WINTON GROUP Ltd purchased a new position in shares of Iradimed in the 3rd quarter worth $366,000. 92.34% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

A number of equities analysts have commented on the stock. Roth Capital reissued a “buy” rating on shares of Iradimed in a research note on Monday, April 22nd. Singular Research reaffirmed a “buy” rating on shares of Iradimed in a research note on Monday, April 1st. Finally, Roth Mkm reaffirmed a “buy” rating and set a $65.00 price target on shares of Iradimed in a research note on Monday, April 22nd.

Check Out Our Latest Analysis on IRMD

Iradimed Trading Down 0.2 %

Shares of IRMD stock traded down $0.07 during trading hours on Thursday, reaching $42.12. 28,203 shares of the stock were exchanged, compared to its average volume of 51,000. Iradimed Corporation has a 12-month low of $36.12 and a 12-month high of $51.04. The company’s 50-day moving average price is $42.46 and its 200-day moving average price is $43.49. The firm has a market capitalization of $533.24 million, a price-to-earnings ratio of 29.92 and a beta of 0.86.

Iradimed (NASDAQ:IRMDGet Free Report) last released its quarterly earnings results on Thursday, May 2nd. The medical equipment provider reported $0.32 EPS for the quarter, topping analysts’ consensus estimates of $0.31 by $0.01. The firm had revenue of $17.60 million during the quarter, compared to analysts’ expectations of $17.26 million. Iradimed had a net margin of 26.48% and a return on equity of 24.63%. On average, sell-side analysts expect that Iradimed Corporation will post 1.41 EPS for the current year.

Iradimed Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, May 30th. Shareholders of record on Monday, May 20th will be given a $0.15 dividend. The ex-dividend date of this dividend is Friday, May 17th. This represents a $0.60 annualized dividend and a yield of 1.42%. Iradimed’s dividend payout ratio (DPR) is 42.55%.

About Iradimed

(Free Report)

IRADIMED CORPORATION develops, manufactures, markets, and distributes magnetic resonance imaging (MRI) compatible medical devices and related accessories, and disposables and services in the United States and internationally. It offers MRidium MRI compatible intravenous (IV) infusion pump system with associated disposable IV tubing sets; MRI compatible patient vital signs monitoring system; and 3600 FMD1 with RALU ferromagnetic detection device.

Recommended Stories

Want to see what other hedge funds are holding IRMD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Iradimed Corporation (NASDAQ:IRMDFree Report).

Institutional Ownership by Quarter for Iradimed (NASDAQ:IRMD)

Receive News & Ratings for Iradimed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Iradimed and related companies with MarketBeat.com's FREE daily email newsletter.